Form 4: Arcturus Therapeutics Executive Granted Stock Options

Lance Kurata, Chief Legal Officer of Arcturus Therapeutics, was granted stock options to purchase 60,000 shares of common stock on December 16, 2024.

Summary

• Lance Kurata, the Chief Legal Officer of Arcturus Therapeutics Holdings Inc., was granted stock options on December 16, 2024.
• The options allow Kurata to purchase 60,000 shares of Arcturus Therapeutics' common stock at an exercise price of $16.24 per share.
• These options were granted under the company's Amended and Restated 2019 Omnibus Equity Incentive Plan.
• The options vest 25% on December 16, 2025, and the remaining 75% vests in equal monthly increments over the following 36 months.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

This document does not contain forward-looking statements about the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Moderna and BioNTech also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Legal Officer to contribute to the company's success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates